Trial Profile
Additional research on biomarkers in "Phase II study of panitumumab rechallenge in the third-line therapy in patients with KRAS wild-type metastatic colorectal cancer (JACCRO CC-09) "
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Feb 2020
Price :
$35
*
At a glance
- Drugs Panitumumab (Primary)
- Indications Colorectal cancer
- Focus Biomarker; Pharmacodynamics
- 25 Jan 2020 Results of post-hoc biomarker study investigating an association between RAS status in ctDNA and clinical outcomes in the JACCRO phase II trials, presented at the 2020 Gastrointestinal Cancers Symposium.
- 08 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 17 Dec 2014 New trial record